Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Rhea-AI Summary

Puma Biotechnology (NASDAQ: PBYI) has announced its participation in the Barclays 27th Annual Global Healthcare Conference. The company's Chairman, CEO, President and Founder, Alan H. Auerbach, will deliver a corporate overview presentation at 2:00 p.m. ET on Tuesday, March 11 at the Loews Miami Beach.

The presentation will be accessible through a live webcast on the company's website at pumabiotechnology.com. For those unable to attend, the presentation will remain available for replay on the website for 30 days following the event.

LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach.

A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.

In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.

Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250305372281/en/

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

info@pumabiotechnology.com

ir@pumabiotechnology.com

David Schull or Olipriya Das, Russo Partners, +1 212 845 4200

david.schull@russopartnersllc.com

olipriya.das@russopartnersllc.com

Source: Puma Biotechnology, Inc.

FAQ

When is Puma Biotechnology (PBYI) presenting at the Barclays Healthcare Conference?

Puma Biotechnology will present at 2:00 p.m. ET on Tuesday, March 11, at the Barclays 27th Annual Global Healthcare Conference.

How can investors watch Puma Biotechnology's (PBYI) Barclays conference presentation?

Investors can watch the presentation via live webcast on Puma Biotechnology's website (pumabiotechnology.com). A replay will be available for 30 days.

Where is the Barclays Healthcare Conference featuring PBYI being held?

The conference is being held at the Loews Miami Beach.

Who will be presenting for Puma Biotechnology at the Barclays conference?

Alan H. Auerbach, who serves as Chairman, CEO, President and Founder of Puma Biotechnology, will present the company overview.